- Home
- YOUL vs SERA Comparison
YOUL vs SERA Comparison
Compare YOUL & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YOUL | SERA |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.9M | 79.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | YOUL | SERA |
|---|---|---|
| Price | $0.88 | $1.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.6K | 17.2K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | $554.81 |
| Revenue Next Year | N/A | $517.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.19 |
| 52 Week Low | $0.78 | $1.37 |
| 52 Week High | $4.40 | $4.09 |
Technical Indicators
Market Signals| Indicator | YOUL | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 40.01 |
| Support Level | $0.80 | $1.72 |
| Resistance Level | $1.14 | $2.41 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 1.28 | 0.00 |
Price Performance
Historical ComparisonAbout YOUL Youlife Group Inc. American Depositary Shares
Youlife Group Inc is a blue-collar lifetime service provider with a nationwide network of 25 vocational schools under school management model and 25 curriculum development projects, covering a total of 37 cities or counties under 16 provinces of China.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.